HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer BioPharmaceutical United States

In Brief

This article was originally published in The Tan Sheet

  • News

Executive Summary

Pharma vets acquire Nutrition 21 assets; FDA approves Perrigo’s generic Mucinex; Pfizer closes Ferrosan consumer health deal; DEA allows PSE log flexibility; and more OTC drug and nutritional product market news In Brief

You may also be interested in...



Nutrition 21 Files For Bankruptcy, Hamstrung By Finished Product Detour

Ingredient developer Nutrition 21 filed for Chapter 11 bankruptcy protection and is soliciting bidders for its assets following an unsuccessful transition into the finished nutritional product space.

In Brief

Watson prevails in Mucinex patent ruling

Pfizer Buys Ferrosan Consumer Unit, Expands In Russia And Northern Europe

Pfizer expands its distribution in the Nordic states and Russia markets with the acquisition of the Danish firm Ferrosan's consumer health care unit.

Table

View full table

Topics

Related Companies

Tags:
Consumer BioPharmaceutical United States
Latest Headlines

Stada’s Natures Aid Expands UK Children’s Wellness Lines

E.l.f. Facing Off Against Beauty Giants: Third Among Mass Market Brands As Sales Jump 78%

Homeopathics, Supplements, OTC Medicines Overlap In Pharmacists’ ‘Over-The-Counter’ Survey

People On The Move: Appointments At AESGP, Alliance Pharma, FSE, Venture Life

See All
UsernamePublicRestriction

Register

RS125191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By